Global Cervical Cancer Treatment Market Size, Share, Forecast Report, 2020-2027

The cervix is the lower part of the uterus that connects to the vagina. Cervical cancer develops in the cells of the cervix. Strains of Human Papillomavirus (HPV), a sexually transmitted infection, play a role in causing most of the cervical cancers. The disease begins when healthy cells acquire mutation leading to the uncontrolled growth of cells. These cells form a tumor which invades the nearby tissues. Squamous cell carcinomas, adenocarcinomas, and adenosquamous carcinomas are three types of cervical cancers. Squamous cell carcinomas develop from cells in the exocervix while adenocarcinomas develop from gland cells. The cancer cells are said to have features of squamous cells under the microscope. Adenosquamous carcinomas feature both squamous cell carcinomas and adenocarcinomas. Cryosurgery, laser surgery, simple hysterectomy, radical hysterectomy, and trachelectomy are various treatment options for cervical cancer. Cystoscopy, proctoscopy, examination under anesthesia, and imaging studies such as Computed Tomography (CT), Magnetic Resonance Imaging (MRI), intravenous urography, and Positron Emission Tomography (PET scan) are used of the diagnosis of cervical cancer.

The cervical cancer treatment market is mainly driven by the increasing prevalence of cervical cancer and increasing awareness about cervical cancer among women. Furthermore, the increasing demand for early diagnosis and treatment of cervical cancer is also expected to fuel the growth of the market during the review period. However, the high cost of treatment also fuels the growth of the market. The World Health Organization (WHO) stated that cancer was the leading cause of the total number of deaths globally in 2015 and was responsible for 8.8 million deaths.

Global Cervical Cancer Treatment market is expected to grow at a CAGR of 6.5% during the forecast period.
Segments

The global cervical cancer treatment market is segmented on the basis of type, treatment, and end-user.

On the basis of type, the market is segmented into squamous cell carcinomas, adenocarcinomas, and adenosquamous carcinomas.

On the basis of treatment, the market is segmented into surgery, radiation therapy, chemotherapy, targeted therapy, hormone therapy, and others.

Surgery is further segmented into cryosurgery, laser surgery, simple hysterectomy, radical hysterectomy, trachelectomy, and others.

Radiation Therapy is further segmented into external beam radiation and brachytherapy

Chemotherapy is further segmented into cisplatin, carboplatin, paclitaxel, doxorubicin, gemcitabine, bevacizumab, and others.

Targeted therapy is further segmented into bevacizumab and pazopanib.

Hormone therapy is further segmented into oestrogen, progesterone, progestogens, and testosterone.

On the basis of end-user, the market is segmented into cancer care centers, diagnostic centers, pharmacies, and others.
Key Players in the Global Cervical Cancer Treatment Market

Some of the key players in this market are Pfizer Inc., GlaxoSmithKline, Bristol-Myers Squibb Company, ALLERGAN, Actavis Pharma Company, Eli Lilly and Company, Alnylam Pharmaceuticals, Inc, Hetero, Biocon, Novartis, Genentech USA, and others.